SDI in practice – Investing in Healthcare

E WEB Goal 03

There are now 15 clinics in various states in the United States and we expect they will open eight to ten new clinics each year. We also invest in new medicines and medical equipment when they are in the final research phase. The medicines and equipment have then already gone through two rounds of research, but the third round is often the most expensive because, for example, the medicine has to be tested on many people. A group of experts then takes over the last phase of the research, conditionally that, after approval, part of the returns flow back to the investors when the drugs are distributed.

Also, for our clients we invest in new medical technology. New medical technology is seen as one of the primary solutions for the healthcare sectors worldwide, which have come under extreme pressure during the COVID-19 pandemic. Since 2016, PFZW’s impact mandate has allowed us to invest in new medical technology. In building a listed impact portfolio, medical technology plays an important role because it offers solutions for more efficient and effective care. We now have several investments in this medtech sector that are driven by a number of trends, such as digitization, automation, personalized care, better diagnostics. Our investment in Japanese medical technology company Terumo fits into this. Terumo makes dotter treatments cheaper and more efficient, and the current overload of care shows well how necessary that is. New medical technology will be able to make an important contribution to a future-proof healthcare infrastructure. In addition to the short-term cost benefits that such technology brings, it is also about achieving long-term gains: with an ever-increasing demand for care due to an aging population, healthcare personnel will become scarce by definition and will need to be deployed as efficiently as possible.